Compare Citius Pharmaceuticals Inc (CTXR) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Public Storage — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Public Storage trades at $287.39 (market cap $53.35B). The key difference: Public Storage is far larger — about 3917× Citius Pharmaceuticals Inc's market cap, and Public Storage pays a 4.2% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Public Storage for 130 Days on average.
| CTXR | PSA | |
|---|---|---|
Market Cap | $13.62M | $53.35B |
Volume | 132,438 | 1,176,034 |
Sector | Health | Real Estate |
52-Week High | $1.82 | $330.47 |
52-Week Low | $0.48 | $258.44 |
Typical Hold Time | 16 Days | 130 Days |
Enterprise Value | $3.79M | $67.62B |
Dividend Yield | — | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Public Storage (PSA) trades at $286.07, up 1.45% with recent earnings beats and strong profitability metrics including 41.8% net income margin. Technical indicators show bearish momentum with support at $277, while fundamentals reveal stable revenue growth and a $3.00 dividend. The company recently completed its Public Storage Canada acquisition and issued C$400 million in senior notes.
The stock presents a mixed outlook with analyst consensus target of $328.33 offering 15% upside, though technical weakness and valuation premiums pose risks. Key opportunities include operational momentum and reliable yield, while headwinds include oversupply concerns and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
